



RUCHI NAHAR

Research Analyst

SUPRIYA LIFESCIENCE LTD

DATE 03 JULY 2024

About Company


Supriya Lifescience Limited headquartered in Mumbai, India is a public listed generic pharmaceutical company established in 1987 dedicated to developing, commercializing APIs & FDFs to treat patients with various diseases and infections. The API facility located at Lote, Maharashtra, India is multiple times USFDA, EDQM/EUGMP approved, and Health Canada approved whereas the Formulation facility located at Ambernath, Mumbai, India is EUGMPcompliant.

Supriya Lifescience Ltd. has presence in API Manufacturing with focus in products of various therapeutic segments like – Anti-Histamine, Anti-Allergics, Vitamins, Anaesthetics, Anti-Asthmatics etc.


OUR RECOMMENDATION:

MOMENTUM SWING: BUY SUPRIYA LIFESCIENCES 405-408 TARGETS 437-463 STOP LOSS BELOW 382.


| MARKET CAP | P/E | DIVIDEND YIELD | ROCE | ROE | FACE VALUE | 3 YEARS SALES GROWTH | 3 YEARS PROFIT GROWTH |
|---------------|-----|----------------|------|-----|------------|----------------------|-----------------------|
| RS. 3,268 CR. | 28 | 0.15% | 22% | 16% | 2.00 | 13% | -1% |



QOQ NET PROFIT (IN CR.)



SHAREHOLDING PATTERN MARCH 24





Analyst View

Supriya lifesciences clearly gave breakout on daily chart and gave strong closing in the previous trading session. The stock bounced back from the support of 34 EMA and sustained above super trend indicator. The rising volume in 5 min chart and breakout indicates that stock is expected to give a bullish trend. Borrowing has been significantly reduced in last three years. In the last 3 quarters Net Profit has jumped significantly from Rs.24 cr. to Rs.37 cr. On the basis of above information we gave Buy signal in the stock, also the breakout shows a momentum in short term. Hence buy recommendation was given in the stock.

DISCLAIMER

I, **Ruchi Nahar**, SEBI Registered Research Analyst (**INH000014544**) comply with the qualification and certification requirements under SEBI (Research Analyst) Regulations, 2014. I have been working in the Financial Markets for over 21 years. All of the views expressed in research reports and recommendations issued by me reflect my personal views about the subject company or companies at the given point of time and I do not receive/accept any kind of compensation, directly or indirectly related to specific recommendations or views expressed in reports issued by me. I/my relatives do not at any point of time of issuing the reports have any material conflict of interest in the subject company neither I was/am/will be engaged in market making activity for the subject company. The investments discussed or views expressed in reports and recommendations issued by me may not be suitable for all investors. The user assumes the entire risk of any use made of this information. I nor any person connected with my report, accepts any liability arising from the use of research document. The recipients of research document should rely on their own investigations and should consult their own financial advisors to determine merit and risks of such investments based on their own risk appetite. Price and value of the investments referred to in this material may go up or down. Past performance is not a guide for future performance. Certain transactions including those involving futures, options and other derivatives as well as non-investment grade securities involve substantial risk and are not suitable for all investors. Reports and recommendations based on technical analysis centres on studying charts of a stock's price movement and trading volume, as opposed to focusing on a company's fundamentals and as such, may not match with a report on a company's fundamentals. Opinions expressed in research reports & recommendations will be based on the current opinions as of the date appearing in research report & recommendations. While I endeavour to update on a reasonable basis the information discussed in research reports, there may be regulatory, compliance, or other reasons that prevent me from doing so. Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without notice. So far as reports include current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed. Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI , and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

A handwritten signature in blue ink that reads "Ruchi Nahar". The signature is written in a cursive style and is underlined with a single horizontal stroke.